Evommune, INC. (EVMN) — SEC Filings
Latest SEC filings for Evommune, INC.. Recent 8-K filing on Apr 13, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Evommune, INC. on SEC EDGAR
Overview
Evommune, INC. (EVMN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Dec 11, 2025: Evommune, Inc. reported a net loss of $40.6 million for the nine months ended September 30, 2025, an improvement from the $46.1 million net loss in the prior year period. License revenue significantly increased to $13.0 million for the nine months ended September 30, 2025, up from $7.0 million in th
Sentiment Summary
Across 5 filings, the sentiment breakdown is: 2 neutral, 3 mixed. The dominant filing sentiment for Evommune, INC. is mixed.
Filing Type Overview
Evommune, INC. (EVMN) has filed 2 8-K, 1 10-Q, 1 S-1/A, 1 S-1 with the SEC between Oct 2025 to Apr 2026.
Filings by Year
Recent Filings (5)
- 8-K Filing — 8-K · Apr 13, 2026
-
Evommune Narrows Loss on Revenue Jump, Secures $65M in New Funding
— 10-Q · Dec 11, 2025 Risk: high
Evommune, Inc. reported a net loss of $40.6 million for the nine months ended September 30, 2025, an improvement from the $46.1 million net loss in the prior ye - 8-K Filing — 8-K · Nov 7, 2025
-
Evommune IPO Targets $15-$17/Share Amid Promising Phase 2 Data
— S-1/A · Oct 17, 2025 Risk: high
Evommune, Inc. (EVMN) is a clinical-stage biotechnology company focused on chronic inflammatory diseases, with two product candidates, EVO756 and EVO301, in Pha -
Evommune Files S-1 for IPO, Advances Chronic Inflammation Pipeline
— S-1 · Oct 9, 2025 Risk: high
Evommune, Inc. (EVMN) is a clinical-stage biotechnology company focused on chronic inflammatory diseases, filing an S-1 for its initial public offering. The com
Risk Profile
Risk Assessment: Of EVMN's 3 recent filings, 3 were flagged as high-risk, 0 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
Key financial metrics from Evommune, INC.'s most recent 10-Q filing (Dec 11, 2025):
- Revenue: $13.0M
- Net Income: -$40.6M
- EPS: -$8.07
- Debt-to-Equity: N/A
- Cash Position: $26.8M
- Operating Margin: -387.3%
- Total Assets: $84.5M
- Total Debt: $10.7M
Key Executives
- Luis Peña
Industry Context
Evommune operates in the biotechnology sector, a highly competitive and capital-intensive industry focused on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success often hinges on the efficacy and safety of drug candidates demonstrated through clinical trials.
Top Tags
Biotechnology (3) · Drug Development (3) · IPO (2) · Clinical Stage (2) · Inflammatory Diseases (2) · Clinical Trials (1) · Capital Raise (1) · Net Loss (1) · R&D Expenses (1) · License Revenue (1)
Key Numbers
- Net Loss: $40.6M — Reduced from $46.1M in prior year period for nine months ended Sep 30, 2025
- License Revenue: $13.0M — Increased from $7.0M in prior year period for nine months ended Sep 30, 2025
- Proceeds from Preferred Stock: $65.2M — New capital raised in nine months ended Sep 30, 2025
- Research and Development Expenses: $53.6M — Increased from $46.4M in prior year period for nine months ended Sep 30, 2025
- Cash and Cash Equivalents: $26.8M — Increased from $16.3M at Dec 31, 2024
- Net Cash Used in Operating Activities: $59.7M — Increased from $39.7M in prior year period for nine months ended Sep 30, 2025
- Total Current Liabilities: $10.4M — Decreased from $28.0M at Dec 31, 2024
- Change in fair value of convertible preferred stock forward: $8.9M — Positive impact on other income, net for nine months ended Sep 30, 2025
- Common Stock Shares Outstanding: 31,524,093 — As of December 10, 2025
- Basic and Diluted Net Loss Per Share: $8.07 — For the three months ended September 30, 2025, improved from $10.47 in prior year
- Common Stock Offered: 9,375,000 Shares — Number of shares Evommune, Inc. is offering in its initial public offering.
- Low IPO Price Range: $15.00 — Expected initial public offering price per share.
- High IPO Price Range: $17.00 — Expected initial public offering price per share.
- Underwriters' Over-allotment Option: 1,406,250 shares — Additional shares underwriters can purchase to cover over-allotments.
- CIndU Patient Improvement: 70% — Percentage of 27 observed patients in Phase 2 CIndU trial demonstrating improvement at four weeks with EVO756.
Frequently Asked Questions
What are the latest SEC filings for Evommune, INC. (EVMN)?
Evommune, INC. has 5 recent SEC filings from Oct 2025 to Apr 2026, including 2 8-K, 1 10-Q, 1 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EVMN filings?
Across 5 filings, the sentiment breakdown is: 2 neutral, 3 mixed. The dominant sentiment is mixed.
Where can I find Evommune, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Evommune, INC. (EVMN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Evommune, INC.?
Key financial highlights from Evommune, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EVMN?
The investment thesis for EVMN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Evommune, INC.?
Key executives identified across Evommune, INC.'s filings include Luis Peña.
What are the main risk factors for Evommune, INC. stock?
Of EVMN's 3 assessed filings, 3 were flagged high-risk, 0 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Evommune, INC.?
Forward guidance and predictions for Evommune, INC. are extracted from SEC filings as they are enriched.